Who Owns Metagenomi Therapeutics Stock?
NASDAQ: MGXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 18.72%
- Held by insiders
- 19.02%
- Institutional holders
- 53
- Institutions 18.7%
- Insiders 19.0%
- Public and other 62.3%
Who owns Metagenomi Therapeutics stock?
Institutional investors own about 18.7% of Metagenomi Therapeutics's shares, spread across 53 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 19.02% of MGX.
The largest institutional holders are Vanguard Capital Management LLC (2.85%), Renaissance Technologies, LLC (1.97%) and Catalio Capital Management, LP (1.40%). Together, the top 10 institutions control 13.2% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their MGX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MGX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vanguard Capital Management LLC | 1.08M | 2.85% | +1.9% |
| Renaissance Technologies, LLC | 742.40K | 1.97% | -5.8% |
| Catalio Capital Management, LP | 528.99K | 1.40% | 0.0% |
| Peapod Lane Capital LLC | 525.02K | 1.39% | +1.6% |
| Two Sigma Investments, LP | 513.70K | 1.36% | +3.4% |
| Bridgeway Capital Management, LLC | 400.30K | 1.06% | +1.1% |
| Wells Fargo & Company | 379.51K | 1.00% | +87.8% |
| Geode Capital Management, LLC | 288.67K | 0.76% | -19.4% |
| Pura Vida Investments, Llc | 264.39K | 0.70% | 0.0% |
| Blackrock Inc. | 257.63K | 0.68% | +11.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MGX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 741.41K | 1.96% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 327.10K | 0.87% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 315.46K | 0.84% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 136.44K | 0.36% |
| iShares Trust-iShares Micro-Cap ETF | 94.85K | 0.25% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 47.21K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 36.09K | 0.10% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 20.83K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 13.58K | 0.04% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 6.88K | 0.02% |
Frequently asked questions
Who is the largest shareholder of Metagenomi Therapeutics?
Vanguard Capital Management LLC is the largest institutional shareholder of MGX, owning 2.85% of shares outstanding (1.08M shares) as of its latest 13F filing.
What percentage of Metagenomi Therapeutics is owned by institutions?
Institutions own about 18.7% of MGX shares and 23.1% of the public float.
How much of Metagenomi Therapeutics do insiders own?
Insiders, such as officers and directors, own about 19.02% of MGX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.